HK1223929A1 - -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 - Google Patents
-氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型Info
- Publication number
- HK1223929A1 HK1223929A1 HK16112165.6A HK16112165A HK1223929A1 HK 1223929 A1 HK1223929 A1 HK 1223929A1 HK 16112165 A HK16112165 A HK 16112165A HK 1223929 A1 HK1223929 A1 HK 1223929A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diazanaphthalene
- dihydro
- amino
- sodium salt
- crystalline forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10002067 | 2010-03-01 | ||
EP10075744 | 2010-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1223929A1 true HK1223929A1 (zh) | 2017-08-11 |
Family
ID=43828190
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112165.6A HK1223929A1 (zh) | 2010-03-01 | 2016-10-24 | -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 |
HK16112162.9A HK1223836A1 (zh) | 2010-03-01 | 2016-10-24 | -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112162.9A HK1223836A1 (zh) | 2010-03-01 | 2016-10-24 | -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 |
Country Status (23)
Country | Link |
---|---|
US (2) | US8772294B2 (zh) |
EP (2) | EP2774920A1 (zh) |
JP (2) | JP6061081B2 (zh) |
KR (1) | KR101770011B1 (zh) |
CN (3) | CN105859634B (zh) |
AU (1) | AU2011223226B2 (zh) |
BR (1) | BR112012021857B1 (zh) |
CA (1) | CA2791327C (zh) |
CH (1) | CH704794B1 (zh) |
CY (1) | CY1115585T1 (zh) |
DK (1) | DK2542535T3 (zh) |
ES (1) | ES2487221T3 (zh) |
HK (2) | HK1223929A1 (zh) |
HR (1) | HRP20140752T1 (zh) |
IL (1) | IL221680A (zh) |
NZ (1) | NZ601689A (zh) |
PL (1) | PL2542535T3 (zh) |
PT (1) | PT2542535E (zh) |
RS (1) | RS53492B1 (zh) |
RU (1) | RU2585677C2 (zh) |
SI (1) | SI2542535T1 (zh) |
WO (1) | WO2011107295A1 (zh) |
ZA (1) | ZA201206264B (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105859634B (zh) * | 2010-03-01 | 2019-06-28 | 梅特里奥药品股份公司 | 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型 |
US10258620B2 (en) | 2014-12-18 | 2019-04-16 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form |
KR102535960B1 (ko) * | 2016-02-16 | 2023-05-23 | 메트리오팜 아게 | 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 새로운 결정질 형태 |
CN109071461B (zh) * | 2016-02-16 | 2022-06-21 | 麦翠奥制药公司 | 制备5-氨基-2,3-二氢酞嗪-1,4-二酮结晶体的方法 |
EP3248602A1 (en) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae |
RU2625267C1 (ru) * | 2016-09-22 | 2017-07-12 | Общество с ограниченной ответственностью "АБИДАФАРМА" | Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты |
CA3042956A1 (en) * | 2016-11-07 | 2018-05-11 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis |
CN106810501B (zh) * | 2017-01-23 | 2019-09-10 | 湖北新德晟材料科技有限公司 | 一种利用一锅法合成鲁米诺或异鲁米诺的方法 |
RU2635769C1 (ru) * | 2017-02-08 | 2017-11-15 | Адмир Мусаевич Абидов | Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения |
RU2673452C1 (ru) * | 2017-08-15 | 2018-11-27 | Межрегиональное общественное учреждение "Институт инженерной физики" | Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия |
EP3511325A1 (en) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
EP3870175A1 (en) * | 2018-10-26 | 2021-09-01 | Immunopharma Plus D.o.o | Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis |
EP3858328A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
EP3858358A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
EP4125802A1 (en) | 2020-03-25 | 2023-02-08 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury |
JP2023529022A (ja) | 2020-06-10 | 2023-07-06 | メトリオファーム アーゲー | コロナウイルス感染症の治療のための化合物 |
EP3981405A1 (en) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
AU2021304254A1 (en) | 2020-07-09 | 2023-02-16 | Metriopharm Ag | Glucocorticoid-sparing agent |
CN116963738A (zh) | 2020-12-02 | 2023-10-27 | 麦翠奥制药公司 | 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺 |
RU2756568C1 (ru) * | 2021-03-24 | 2021-10-01 | Акционерное общество "Щелково Агрохим" | Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме |
EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
EP4209219A1 (en) | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
EP4248963A1 (en) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089086C (zh) * | 1988-03-31 | 2002-08-14 | 兰德尔·L·米尔斯 | 鲁米纳得类药物 |
CH683965A5 (it) * | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. |
CH683966A5 (it) | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa. |
RU2113222C1 (ru) | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
RU2138264C1 (ru) | 1999-05-06 | 1999-09-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата галавит |
WO2001072305A1 (fr) * | 2000-03-28 | 2001-10-04 | Ramazanov, Ziadin Magomedovich | Composition médicamenteuse et procédé de fabrication correspondant |
RU2169139C1 (ru) | 2000-08-02 | 2001-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона |
RU2167659C1 (ru) | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ коррекции иммунной системы живого организма |
RU2211036C2 (ru) | 2001-11-20 | 2003-08-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
RU2222327C2 (ru) | 2002-03-22 | 2004-01-27 | Общество с ограниченной ответственностью "Абидофарма" | Способ получения лекарственного препарата |
US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
RU2238730C1 (ru) | 2003-02-17 | 2004-10-27 | Абидов Муса Тажудинович | Лекарственный препарат |
RU2302863C2 (ru) | 2003-04-18 | 2007-07-20 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) |
CN1217193C (zh) * | 2003-07-30 | 2005-08-31 | 中国药科大学 | 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法 |
AU2003301513A1 (en) | 2003-08-04 | 2005-02-15 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
US20100222584A1 (en) | 2009-02-06 | 2010-09-02 | Bach Pharma, Inc. | Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them |
CN105859634B (zh) * | 2010-03-01 | 2019-06-28 | 梅特里奥药品股份公司 | 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型 |
-
2011
- 2011-03-01 CN CN201610087179.8A patent/CN105859634B/zh active Active
- 2011-03-01 SI SI201130233T patent/SI2542535T1/sl unknown
- 2011-03-01 PT PT117104232T patent/PT2542535E/pt unknown
- 2011-03-01 NZ NZ601689A patent/NZ601689A/en unknown
- 2011-03-01 JP JP2012555335A patent/JP6061081B2/ja active Active
- 2011-03-01 PL PL11710423T patent/PL2542535T3/pl unknown
- 2011-03-01 AU AU2011223226A patent/AU2011223226B2/en active Active
- 2011-03-01 CN CN201610087203.8A patent/CN105726541A/zh active Pending
- 2011-03-01 DK DK11710423.2T patent/DK2542535T3/da active
- 2011-03-01 CA CA2791327A patent/CA2791327C/en active Active
- 2011-03-01 EP EP14001134.7A patent/EP2774920A1/de not_active Withdrawn
- 2011-03-01 ES ES11710423.2T patent/ES2487221T3/es active Active
- 2011-03-01 KR KR1020127025234A patent/KR101770011B1/ko active IP Right Grant
- 2011-03-01 BR BR112012021857-3A patent/BR112012021857B1/pt active IP Right Grant
- 2011-03-01 CN CN201180011760.7A patent/CN102971300B/zh active Active
- 2011-03-01 US US13/582,522 patent/US8772294B2/en active Active
- 2011-03-01 CH CH01123/12A patent/CH704794B1/de not_active IP Right Cessation
- 2011-03-01 WO PCT/EP2011/001124 patent/WO2011107295A1/de active Application Filing
- 2011-03-01 RS RSP20140416 patent/RS53492B1/en unknown
- 2011-03-01 RU RU2012141274/04A patent/RU2585677C2/ru active
- 2011-03-01 EP EP11710423.2A patent/EP2542535B1/de active Active
-
2012
- 2012-08-20 ZA ZA2012/06264A patent/ZA201206264B/en unknown
- 2012-08-29 IL IL221680A patent/IL221680A/en active IP Right Grant
-
2014
- 2014-04-08 US US14/247,626 patent/US9079863B2/en active Active
- 2014-08-04 CY CY20141100589T patent/CY1115585T1/el unknown
- 2014-08-06 HR HRP20140752AT patent/HRP20140752T1/hr unknown
-
2016
- 2016-06-09 JP JP2016115125A patent/JP6206689B2/ja active Active
- 2016-10-24 HK HK16112165.6A patent/HK1223929A1/zh unknown
- 2016-10-24 HK HK16112162.9A patent/HK1223836A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223929A1 (zh) | -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 | |
ZA201206440B (en) | [5,6]heterocyclic compound | |
PL2521450T3 (pl) | Grzybobójcze związki heterocykliczne | |
IL225770A0 (en) | Heterocyclic compounds | |
IL221442A0 (en) | Heterocyclic compound | |
GB0908293D0 (en) | Herbicidal compounds | |
GB0905441D0 (en) | Herbicidal compounds | |
BRPI1015540A2 (pt) | ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750'' | |
ZA201107772B (en) | Substituted spiro-amide compounds | |
EP2519525A4 (en) | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | |
ZA201300950B (en) | Heterocyclic compound | |
GB2470828B (en) | Fish finder | |
EP2519522A4 (en) | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | |
EP2555766A4 (en) | ANTIMETASTATIC COMPOUNDS | |
EP2616453A4 (en) | ANTIMETASTATIC COMPOUNDS | |
ZA201205726B (en) | Substituted naphthalenyl-pyrimidine compounds | |
GB0917934D0 (en) | Herbicidal compounds | |
IL216338A0 (en) | Heterocyclic antiviral compound | |
IL218500A0 (en) | Apogossypolone derivatives as anticaner agents | |
EP2609093A4 (en) | SALT CONNECTION | |
EP2632255A4 (en) | HETEROCYCLIC DIAZENIUM DIOLATE DERIVATIVES | |
IL217898A0 (en) | Crystalline form i rosuvastatin zinc salt | |
PT2274977E (pt) | Anzol | |
GB0916267D0 (en) | Herbicidal compounds | |
EP2527343A4 (en) | HETEROCYCLIC CONNECTION WITH AN AOLA GROUP |